This site is intended for US healthcare
professionals only.
VERONA PATHWAY PLUS®:

Providing Patients with Support
on the Pathway to Treatment

Verona Pathway Plus is a patient support program that is available to your patients during treatment. It provides tools, resources, education, and assistance to help navigate access and affordability issues or challenges for patients who have been prescribed Ohtuvayre.

Ohtuvayre prescriptions are filled through the Verona Pathway Plus network of Specialty Pharmacies. Reach out for more information about how to submit a prescription for your patients.

Verona Pathway Plus logo

Call:
1-833-372-8492

Back to top
Enroll Your Patient
Financial Coverage
Dedicated Support Team
Back to top

Submitting a prescription for Ohtuvayre

Receive coverage and access support for your patient taking Ohtuvayre through Verona Pathway Plus and direct delivery of prescriptions to your patients through our Durable Medical Equipment (DME) accredited Specialty Pharmacy (SP) network.

Step 1

Complete the Ohtuvayre Prescription and Patient Enrollment & Consent Form
  • The Prescription Form includes the Ohtuvayre and DME prescriptions
  • Ensure your patient completes the Patient Consent Form during the office visit to expedite Verona Pathway Plus enrollment for additional support

Step 2

Submit via Fax

Fax the Ohtuvayre Prescription and Patient Enrollment & Consent Form to
1-833-392-8999.

Verona Pathway Plus Offers Support Throughout Treatment

Coverage and Affordability

Support and Education

Prescription Fulfillment
through SP

Financial Assistance

Copay Program

Eligible commercially insured patients may pay as little as $0 per month for Ohtuvayre.*

Ohtuvayre Bridge Program

Verona Pathway Plus may be able to help with starting treatment if there is a coverage delay with your patient’s insurance. You must check the Bridge Program Prescription on the Patient Enrollment Form for your patient to be considered for the Bridge Program.†

Patient Assistance Program

For patients who do not have insurance, are underinsured, or are in a situation where Ohtuvayre is not covered by their insurance plan, Verona Pathway Plus may be able to help.

  • Verona Pathway Plus can check to see if your patient qualifies, based on the program’s eligibility criteria.

*Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.

† Subject to eligibility. Restrictions apply.

Our Dedicated Team is Available to Your Patients

Care Coordinators

Verona Pathway Plus Care Coordinators will help support patients throughout treatment by answering questions and providing access and product information. This includes:

  • Benefits investigations (BIs)
  • Medication and nebulizer access
  • Providing eligible patients with financial assistance options
  • Information about the appropriate Specialty Pharmacy (SP) in our Durable Medical Equipment (DME)-accredited SP network
  • Offering support and education throughout Ohtuvayre treatment

Field Access Managers (FAMs)

FAMs will provide access and reimbursement education and support resources to help your patients navigate coverage from payers. This includes:

  • Information about how to submit prescriptions for Ohtuvayre through Verona Pathway Plus
  • Insurance coverage education and support
  • Information to help address access issues, including prior authorizations (PAs) and appeals processes

Prescriptions are filled only through our DME-accredited SP network. They will work with your office and patients in order to:

  • Assist with the PA process
  • Answer questions, offer treatment support, and provide education about Ohtuvayre
  • Ship Ohtuvayre and necessary supplies directly to your patients
  • Provide refill management by text and Online Portal

If your practice needs to contact a Care Coordinator, please call us Monday through Friday, between 8:00 AM and 8:00 PM ET.

A Care Coordinator can also connect you to a pharmacist.

Call: 1-833-372-8492

Learn more about Ohtuvayre

OHTUVAYRE is contraindicated in patients with hypersensitivity to ensifentrine or any component of this product.

Acute Episodes of Bronchospasm: OHTUVAYRE should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. OHTUVAYRE has not been studied in the relief of acute symptoms and extra doses of OHTUVAYRE should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting bronchodilator.

Paradoxical Bronchospasm: As with other inhaled medicines, OHTUVAYRE may produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs following dosing with OHTUVAYRE, it should be treated immediately with an inhaled, short-acting bronchodilator. OHTUVAYRE should be discontinued immediately and alternative therapy should be instituted.

Psychiatric Events Including Suicidality: Treatment with OHTUVAYRE is associated with an increase in psychiatric adverse reactions. Psychiatric events including suicide-related adverse reactions were reported in clinical studies in patients who received OHTUVAYRE (1 suicide attempt and 1 suicide). Additionally, the most commonly reported psychiatric adverse reactions in the pooled 24-week safety population were insomnia (6 patients [0.6%] OHTUVAYRE 3 mg; 2 patients [0.3%] placebo), and anxiety (2 patients [0.2%] OHTUVAYRE 3 mg; 1 patient [0.2%] placebo). Depression-related reactions including depression, major depression, and adjustment disorder with depressed mood occurred in 4 patients [0.4%] receiving OHTUVAYRE and no patients receiving placebo.0.4%] receiving Ohtuvayre and no patients receiving placebo.

Before initiating treatment with OHTUVAYRE, healthcare providers should carefully weigh the risk and benefits of treatment with OHTUVAYRE in patients with a history of depression and/or suicidal thoughts or behavior. Patients, their caregivers, and families should be advised of the need to be alert for the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts, or other mood changes, and if such changes occur to contact their healthcare provider. Healthcare providers should carefully evaluate the risks and benefits of continuing treatment with OHTUVAYRE if such events occur.

Adverse Reactions: The most common adverse reactions ≥1% in OHTUVAYRE and greater than placebo in the pooled population were back pain 1.8%, hypertension 1.7%, urinary tract infection 1.3%, and diarrhea 1.0%.

These are not all of the possible risks associated with OHTUVAYRE.

Pediatric Use: The safety and effectiveness of OHTUVAYRE have not been established in pediatric patients.

Lactation: There are no data on the presence of ensifentrine in human milk, the effects on the breastfed child, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for OHTUVAYRE and any potential adverse effects on the breastfed child from OHTUVAYRE or from the underlying maternal condition.

Geriatric Use: In clinical trials, patients aged 65 and older showed no overall differences in the safety or effectiveness of OHTUVAYRE compared with younger adults, but greater sensitivity in some older individuals cannot be ruled out.

Hepatic Impairment: Ensifentrine systemic exposure increased by 2.3-fold in subjects with moderate or severe hepatic impairment compared with healthy subjects. Use OHTUVAYRE with caution in patients with hepatic impairment.

Before prescribing OHTUVAYRE, please read the accompanying Prescribing Information. The Patient Information is also available.

To report suspected adverse reactions, contact Verona Pharma, Inc. at 1-888-672-0371.